Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives
Currently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir. Most clinical trials have examined DAAs in combination with standard of care (SOC) regimens. Future therapeutic drugs were...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1155/2013/704912 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545626650312704 |
|---|---|
| author | Hee Bok Chae Seon Mee Park Sei Jin Youn |
| author_facet | Hee Bok Chae Seon Mee Park Sei Jin Youn |
| author_sort | Hee Bok Chae |
| collection | DOAJ |
| description | Currently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir. Most clinical trials have examined DAAs in combination with standard of care (SOC) regimens. Future therapeutic drugs were divided into three categories. They are second-wave protease inhibitors, second-generation protease inhibitors, and polymerase inhibitors. Second-wave protease inhibitors are more improved form and can be administered once a day. Oral drug combinations can be favored because interferon (IFN) not only has to be given as intradermal injection, but also can cause several serious side effects. Combination of drugs with different mechanisms shows a good sustained virological response (SVR). But several mutations are associated with viral resistance to DAAs. Therefore, genotypic resistance data may provide insights into strategies aimed at maximizing SVR rates and minimizing resistance. Combined drug regimens are necessary to prevent the emergence of drug-resistant HCV. Many promising DAA candidates have been identified. Of these, a triple regimen containing sofosbuvir shows promise, and treatment with daclatasvir plus asunaprevir yields a high SVR rate (95%). Oral drug combinations will be standard of care in the near future. |
| format | Article |
| id | doaj-art-131b73c190514b51942efae64daf44d9 |
| institution | Kabale University |
| issn | 1537-744X |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-131b73c190514b51942efae64daf44d92025-02-03T07:25:02ZengWileyThe Scientific World Journal1537-744X2013-01-01201310.1155/2013/704912704912Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future PerspectivesHee Bok Chae0Seon Mee Park1Sei Jin Youn2Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, 1 Sunwhan-ro, Heungdok-gu, Cheongju 361-711, Republic of KoreaDepartment of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, 1 Sunwhan-ro, Heungdok-gu, Cheongju 361-711, Republic of KoreaDepartment of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, 1 Sunwhan-ro, Heungdok-gu, Cheongju 361-711, Republic of KoreaCurrently, two direct-acting antivirals (DAAs) show well-established efficacy against hepatitis C virus (HCV), namely, first-wave protease inhibitors telaprevir and boceprevir. Most clinical trials have examined DAAs in combination with standard of care (SOC) regimens. Future therapeutic drugs were divided into three categories. They are second-wave protease inhibitors, second-generation protease inhibitors, and polymerase inhibitors. Second-wave protease inhibitors are more improved form and can be administered once a day. Oral drug combinations can be favored because interferon (IFN) not only has to be given as intradermal injection, but also can cause several serious side effects. Combination of drugs with different mechanisms shows a good sustained virological response (SVR). But several mutations are associated with viral resistance to DAAs. Therefore, genotypic resistance data may provide insights into strategies aimed at maximizing SVR rates and minimizing resistance. Combined drug regimens are necessary to prevent the emergence of drug-resistant HCV. Many promising DAA candidates have been identified. Of these, a triple regimen containing sofosbuvir shows promise, and treatment with daclatasvir plus asunaprevir yields a high SVR rate (95%). Oral drug combinations will be standard of care in the near future.http://dx.doi.org/10.1155/2013/704912 |
| spellingShingle | Hee Bok Chae Seon Mee Park Sei Jin Youn Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives The Scientific World Journal |
| title | Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives |
| title_full | Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives |
| title_fullStr | Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives |
| title_full_unstemmed | Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives |
| title_short | Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives |
| title_sort | direct acting antivirals for the treatment of chronic hepatitis c open issues and future perspectives |
| url | http://dx.doi.org/10.1155/2013/704912 |
| work_keys_str_mv | AT heebokchae directactingantiviralsforthetreatmentofchronichepatitiscopenissuesandfutureperspectives AT seonmeepark directactingantiviralsforthetreatmentofchronichepatitiscopenissuesandfutureperspectives AT seijinyoun directactingantiviralsforthetreatmentofchronichepatitiscopenissuesandfutureperspectives |